Cytokinetics Q1 Earnings Beat, Aficamten Target Action Date Extended

Cytokinetics, Incorporated (CYTK) reported a net loss of $1.36 per share for the first quarter of 2025, narrower than the Zacks Consensus Estimate of a loss of $1.41. In the year-ago quarter, the company reported a net loss of $1.33 per share. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)The year-over-year deterioration was due to higher operating expenses.Cytokinetics is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and comme ...